In the BioHarmony Drug Report Database

"Preview" Icon

Belatacept

Nulojix (belatacept) is a protein pharmaceutical. Belatacept was first approved as Nulojix on 2011-06-15. It has been approved in Europe to treat graft rejection and kidney transplantation. The pharmaceutical is active against T-lymphocyte activation antigen CD80 and T-lymphocyte activation antigen CD86.

 

Trade Name

 

Nulojix
 

Common Name

 

belatacept
 

ChEMBL ID

 

CHEMBL1742990
 

Indication

 

graft rejection, kidney transplantation
 

Drug Class

 

Receptor molecules, native or modified: T-cells

Image (chem structure or protein)

Belatacept structure rendering